MPAM
TVTX icon

Monarch Partners Asset Management’s Travere Therapeutics TVTX Stock Holding History

Monarch Partners Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-11,760
Closed -$223K – 200
2016
Q4 		$223K Hold
11,760
– – 0.02% 168
2016
Q3 		$263K Buy
+11,760
New +$224K 0.02% 157

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Monarch Partners Asset Management's TVTX Position: Q1 2017 in Review

Monarch Partners Asset Management sold out of Travere Therapeutics (TVTX) in Q1 2017, closing a stake of 11,760 shares — an estimated $223K sold.

Monarch Partners Asset Management first reported a position in TVTX in Q3 2016 and held it in 2 quarters. The position peaked at $263K in Q3 2016. 114 funds tracked by Wall St. Rank hold TVTX as of Q1 2017.

  • Monarch Partners Asset Management reported no remaining Travere Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Monarch Partners Asset Management sold 11,760 Travere Therapeutics shares in Q1 2017, an estimated $223K.
  • Monarch Partners Asset Management first reported a position in Travere Therapeutics in Q3 2016 and held it in 2 quarters.
  • Monarch Partners Asset Management's Travere Therapeutics position peaked at $263K in Q3 2016.
  • 114 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2017.

Based on Monarch Partners Asset Management's 13F filing for Q1 2017, filed 28 Apr 2017.